曲妥珠单抗-美坦新偶联物（T-DM1）在 HER2 阳性乳腺癌伴脑转移中的不断演变的作用。
The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
机构信息
Children's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Medical Oncology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
出版信息
Crit Rev Oncol Hematol. 2019 Nov;143:20-26. doi: 10.1016/j.critrevonc.2019.07.010. Epub 2019 Aug 12.
Approximately 30-50% of advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer patients will develop brain metastases (BMs) during the disease course. Brain metastases may become a main limitation of life expectancy and a half of them will die from brain progression. Even in patients with early HER2-positive breast cancer managed with curative therapy, the risk of brain metastases is also increased. Central nervous system (CNS) may usually present as the first site of recurrence in HER2-positive breast cancer. Local treatments including radiotherapy and surgery are essential while new chemotherapy and biological agents appear to contribute a significant role in the future treatment field of CNS metastases. This article will review recent progresses in HER2-positive breast cancer with BM, with a focus on the efficacy of the HER2 targeted agents-trastuzumab emtansine (T-DM1).
约 30-50%的晚期人表皮生长因子受体 2（HER2）阳性乳腺癌患者在疾病过程中会发展为脑转移（BM）。脑转移可能成为预期寿命的主要限制因素，其中一半患者将死于脑转移进展。即使在接受根治性治疗的早期 HER2 阳性乳腺癌患者中，脑转移的风险也会增加。中枢神经系统（CNS）通常是 HER2 阳性乳腺癌复发的第一部位。局部治疗（包括放疗和手术）至关重要，而新的化疗和生物制剂似乎在 CNS 转移的未来治疗领域发挥重要作用。本文将综述 HER2 阳性乳腺癌伴 BM 的最新进展，重点介绍 HER2 靶向药物曲妥珠单抗-美坦新偶联物（T-DM1）的疗效。
Zotero 插件